Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
AstraZeneca
Cerilliant
Novartis
Chubb
Johnson and Johnson
Fuji
Citi
Boehringer Ingelheim
McKesson

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,231,887

« Back to Dashboard

Which drugs does patent 6,231,887 protect, and when does it expire?

Patent 6,231,887 protects APTIVUS and is included in one NDA.

Protection for APTIVUS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-three patent family members in twenty-two countries.
Summary for Patent: 6,231,887
Title: Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
Abstract:The present invention provides a novel pharmaceutical composition based on the use of a particular amount of basic amine which comprises a pyranone compound as a pharmaceutically active agent, a basic amine in an amount of from about 0.1% to about 10% by weight of the total composition, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. In addition, the composition may further comprises one or more pharmaceutically acceptable oils. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic pyranone compounds.
Inventor(s): Gao; Ping (Portage, MI), Morozowich; Walter (Kalamazoo, MI)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:09/122,927
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form;

Drugs Protected by US Patent 6,231,887

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,231,887

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,121,313 Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds ➤ Sign Up
6,531,139 Self-emulsifying formulation for lipophilic compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,231,887

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 215370 ➤ Sign Up
Austria 225174 ➤ Sign Up
Austria 265847 ➤ Sign Up
Australia 728626 ➤ Sign Up
Australia 728695 ➤ Sign Up
Australia 728698 ➤ Sign Up
Australia 8573798 ➤ Sign Up
Australia 8573898 ➤ Sign Up
Australia 8573998 ➤ Sign Up
Brazil 9810729 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Queensland Health
Fuji
Colorcon
AstraZeneca
UBS
Boehringer Ingelheim
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot